Tempest Therapeutics, Inc. (NASDAQ:TPST – Get Rating) was the recipient of a large growth in short interest in May. As of May 15th, there was short interest totalling 77,900 shares, a growth of 144.2% from the April 30th total of 31,900 shares. Based on an average daily trading volume, of 238,100 shares, the days-to-cover ratio […]
Tempest Therapeutics, Inc. (NASDAQ:TPST – Get Rating) saw a significant growth in short interest in May. As of May 15th, there was short interest totalling 77,900 shares, a growth of 144.2% from the April 30th total of 31,900 shares. Based on an average daily volume of 238,100 shares, the short-interest ratio is currently 0.3 days. […]
Tempest Therapeutics, Inc. (NASDAQ:TPST – Get Rating) saw a significant growth in short interest in May. As of May 15th, there was short interest totalling 77,900 shares, a growth of 144.2% from the April 30th total of 31,900 shares. Based on an average daily volume of 238,100 shares, the short-interest ratio is currently 0.3 days. […]
Tempest Therapeutics, Inc. (NASDAQ:TPST – Get Rating) – Analysts at HC Wainwright boosted their Q2 2023 earnings estimates for Tempest Therapeutics in a research note issued to investors on Thursday, May 11th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($0.64) per share for the quarter, up from their […]
Tempest Therapeutics (NASDAQ:TPST – Get Rating) had its target price increased by LADENBURG THALM/SH SH from $8.00 to $14.00 in a research report report published on Friday morning, The Fly reports. TPST has been the subject of several other research reports. Piper Sandler lowered their target price on shares of Tempest Therapeutics from $10.00 to […]